[caption id="attachment_71590" align="aligncenter" width="500"]
Freepx[/caption]
Mental health is shaped by a wide mix of emotional, physical, social, and environmental influences. It’s not a single dimensional issue that can be solved with a single type of treatment. When someone struggles with anxiety, depression, trauma, or chronic stress, the impact touches every part of life. Thoughts, behaviors, mood, physical energy, sleep, and relationships all shift under the weight of emotional strain.
Because mental health is so deeply interconnected with overall well-being, an approach that considers only one angle often falls short. Treating symptoms without exploring root causes leaves people with temporary relief at best. This is why both holistic and medical perspectives are essential for creating lasting and meaningful improvement.
The Importance of a Holistic Perspective
Holistic care looks at the entire person. Instead of focusing only on the diagnosis or the symptoms, this approach considers what contributes to emotional distress. Factors such as diet,
sleep patterns, daily stress, family dynamics, work pressures, unresolved trauma, and personal beliefs all play important roles in mental well-being.
For many people, mental health symptoms improve significantly when daily routines become healthier and more supportive. Practices like mindfulness, physical movement, grounding techniques, journaling, and lifestyle changes can strengthen emotional resilience and reduce vulnerability to stress. Therapy also serves as a core holistic tool, helping people uncover triggers, patterns, and emotional blocks that influence their current struggles. Over time, these strategies support deeper self-understanding and long-term growth.
Dr. Bell[/caption]
Dr. Jack Bell
Liverpool Heart and Chest Hospital
Liverpool, UK
MedicalResearch.com: What is the background for this study?
Response: Coronary computed tomography angiography (CCTA) is a non-invasive heart scan used in the first-line investigation of patients with suspected stable coronary artery disease (CAD). While CCTA clearly shows blockages in coronary arteries, it is limited in its ability to estimate reduced blood flow, which is necessary to diagnose angina.
An artificial intelligence-based tool (Heartflow) has been developed that analyses CCTA images and provides an estimate of blood flow: CT-derived fractional flow reserve (FFR-CT). The real-world, retrospective English FISH&CHIPS study demonstrated that including FFR-CT as a decision-making tool in the diagnosis of stable CAD reduces the number of subsequent invasive and non-invasive tests performed.
Whether FFR-CT could also be used prognostically, to predict future major cardiovascular events, was not fully understood. Previous studies have had small patient numbers, short follow-up and investigated combined cardiovascular outcomes. We performed an analysis on the national FISH&CHIPS population, which was large enough to determine if FFR-CT adds incremental value to traditional cardiovascular risk factors in predicting cardiovascular outcomes and death.
Dr. Mosnaim[/caption]
Dr. Giselle Mosnaim MD MS FACAAI
Allergist
Division of Allergy and Immunology
Department of Medicine
Northshore University Health System
REMIX-1/-2 Investigator
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment.
The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
